Objective:To understand the depressive and anxiety condition of Han and Korean climacteric residents in community.Methods:1262 climacteric residents including 639 Korean and 623 Han residents selected from eight neighborhood communities were investigated with a Health-Investigating Scale(self-made),the Center for Epidemiological Survey Depression Scale(CES-D) and Self-rating Anxiety Scale(SAS).Results:According to CES-D,there were totally 127(10.12%) met the criteria of depression,in which 69(54.3%) were Korean and 58 were Han(45.7%).By SAS,391(32.24%) residents in which 240(61.4%) Korean and 151(38.6%) Han had anxiety symptoms.Stepwise multi-factorial regression analysis revealed the major factors related to depression were:nationality,income,drink,personality and employed,those related to anxiety were nationality,personality,drink,income and health.Conclusions:There are more depression and anxiety in Korean climacteric people than in Han.

Objective:To investigated the safety and efficacy of donor-derived CD19+ or sequential CD19+ CD22+ chimeric antigen receptor T-cell (CAR-T) therapy in patients with B-cell acute lymphoblastic leukemia (B-ALL) after allogeneic hematopoietic stem cell transplantation (allo-HSCT).Methods:The data of 22 patients with B-ALL who relapsed after allo-HSCT and who underwent donor-derived CAR-T therapy at the Zhujiang Hospital of Southern Medical University and the 920th Hospital of Joint Logistics Support Force of the People’s Liberation Army of China from September 2015 to December 2022 were retrospectively analyzed. The primary endpoint was overall survival (OS), and the secondary endpoints were event-free survival (EFS), complete remission (CR) rate, and Grade 3-4 adverse events.Results:A total of 81.82% ( n=18) of the 22 patients achieved minimal residual disease-negative CR after CAR-T infusion. The median follow-up time was 1037 (95% CI 546–1509) days, and the median OS and EFS were 287 (95% CI 132-441) days and 212 (95% CI 120-303) days, respectively. The 6-month OS and EFS rates were 67.90% (95% CI 48.30%-84.50%) and 58.70% (95% CI 37.92%-79.48%), respectively, and the 1-year OS and EFS rates were 41.10% (95% CI 19.15%-63.05%) and 34.30% (95% CI 13.92%-54.68%), respectively. Grade 1-2 cytokine release syndrome occurred in 36.36% ( n=8) of the patients, and grade 3-4 occurred in 13.64% of the patients ( n=3). Grade 2 and 4 graft-versus-host disease occurred in two patients. Conclusion:Donor-derived CAR-T therapy is safe and effective in patients with relapsed B-ALL after allo-HSCT.